Monday, November 20, 2017 10:17:18 AM
the HeartSentry, a new non-invasive diagnostic tool for accurately measuring
and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner
lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the
company.
• Lexington is in final stages of releasing the product into clinical studies for FDA
approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular
health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized
medicine.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM